

## Humanized Mice Reveal Differential Immunogenicity of Cells Derived from Autologous Induced Pluripotent Stem Cells.

**Journal:** Cell Stem Cell

**Publication Year:** 2015

**Authors:** Tongbiao Zhao, Zhen-ning Zhang, Peter D Westenskow, Dilyana Todorova, Zheng Hu, Tongxiang Lin, Zhili Rong, Jinchul Kim, Jingjin He, Meiyang Wang, Dennis O Clegg, Yong-guang Yang, Kun Zhang, Martin Friedlander, Yang Xu

**PubMed link:** 26299572

**Funding Grants:** Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells, Synthetic Matrices for Stem Cell Growth and Differentiation, Developing induced pluripotent stem cells into human therapeutics and disease models, Induction of immune tolerance to human embryonic stem cell-derived allografts, Stem cell based treatment strategy for Age-related Macular Degeneration (AMD), Training Program in Stem Cell Biology and Engineering, The UCSB Laboratory for Stem Cell Biology and Engineering, UCSB Stem Cell Biology Training Program, Stem cell based treatment strategy for Age-related Macular Degeneration (AMD), Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Polyethylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration

### Public Summary:

The breakthrough of induced pluripotent stem cell (iPSC) technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC (hiPSC)-derived cells is not well understood. Using a humanized mouse model (denoted Hu-mice) reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs exhibit local infiltration of antigen-specific T cells and associated tissue necrosis, indicating immune rejection of certain hiPSC-derived cells. In this context, autologous hiPSC-derived smooth muscle cells (SMCs) appear to be highly immunogenic, while autologous hiPSC-derived retinal pigment epithelial (RPE) cells are immune tolerated even in non-ocular locations. This differential immunogenicity is due in part to abnormal expression of immunogenic antigens in hiPSC-derived SMCs, but not in hiPSC-derived RPEs. These findings support the feasibility of developing hiPSC-derived RPEs for treating macular degeneration.

### Scientific Abstract:

The breakthrough of induced pluripotent stem cell (iPSC) technology has raised the possibility that patient-specific iPSCs may become a renewable source of autologous cells for cell therapy without the concern of immune rejection. However, the immunogenicity of autologous human iPSC (hiPSC)-derived cells is not well understood. Using a humanized mouse model (denoted Hu-mice) reconstituted with a functional human immune system, we demonstrate that most teratomas formed by autologous integration-free hiPSCs exhibit local infiltration of antigen-specific T cells and associated tissue necrosis, indicating immune rejection of certain hiPSC-derived cells. In this context, autologous hiPSC-derived smooth muscle cells (SMCs) appear to be highly immunogenic, while autologous hiPSC-derived retinal pigment epithelial (RPE) cells are immune tolerated even in non-ocular locations. This differential immunogenicity is due in part to abnormal expression of immunogenic antigens in hiPSC-derived SMCs, but not in hiPSC-derived RPEs. These findings support the feasibility of developing hiPSC-derived RPEs for treating macular degeneration.

**Source URL:** <https://www.cirm.ca.gov/about-cirm/publications/humanized-mice-reveal-differential-immunogenicity-cells-derived-autologous>